Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown. METHODS: We studied pathological signs of early metastatic invasion (venous emboli and lymphatic and perineural invasion) in 959 specimens of resected colorectal cancer. The local immune response within the tumor was studied by flow cytometry (39 tumors), low-density-array real-time polymerase-chain-reaction assay (75 tumors), and tissue microarrays (415 tumors). RESULTS: Univariate analysis showed significant differences in disease-free and overall survival according to the presence or absence of histologic signs of early metastatic invasion (P<0.001). Multivariate Cox analysis showed that an early conventional pathological tumor-node-metastasis stage (P<0.001) and the absence of early metastatic invasion (P=0.04) were independently associated with increased survival. As compared with tumors with signs of early metastatic invasion, tumors without such signs had increased infiltrates of immune cells and increased levels of messenger RNA (mRNA) for products of type 1 helper effector T cells (CD8, T-BET [T-box transcription factor 21], interferon regulatory factor 1, interferon-gamma, granulysin, and granzyme B) but not increased levels of inflammatory mediators or immunosuppressive molecules. The two types of tumors had significant differences in the levels of expression of 65 combinations of T-cell markers, and hierarchical clustering showed that markers of T-cell migration, activation, and differentiation were increased in tumors without signs of early metastatic invasion. The latter type of tumors also had increased numbers of CD8+ T cells, ranging from early memory (CD45RO+CCR7-CD28+CD27+) to effector memory (CD45RO+CCR7-CD28-CD27-) T cells. The presence of high levels of infiltrating memory CD45RO+ cells, evaluated immunohistochemically, correlated with the absence of signs of early metastatic invasion, a less advanced pathological stage, and increased survival. CONCLUSIONS: Signs of an immune response within colorectal cancers are associated with the absence of pathological evidence of early metastatic invasion and with prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examination of the lymphocytes that correlated with such beneficial outcomes has repeatedly implicated effector and memory CD8 + T cell and NK cell populations (136-141).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [136]
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Research works printed but not linked: 2
- 10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t · DOI · Paper page
- 10.1002/(sici)1097-0215(19990621)84:3<326::aid-ijc22>3.0.co;2-k · DOI · Paper page
Cited by
Items 801–900 of 1,001
Lee, J., Kefford, R. F., & Carlino, M. S. (2016) · Immunotherapy · doi:10.2217/imt-2016-0022 · Cited by 44
Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling
Sun, X., Liu, S., Wang, D., Zhang, Y., Li, W., Guo, Y., Zhang, H., & Suo, J. (2017) · Oncotarget · doi:10.18632/oncotarget.14834 · Cited by 44
“CRC patients with more T cell infiltration have better outcomes [4, 7, 8].”
BackgroundStromal and intraepithelial tumor‑infiltrating lymphocytes in colorectal carcinoma
Jakubowska, K., Kisielewski, W., Kańczuga‐Koda, L., Koda, M., & FAMULSKI, W. (2017) · Oncology Letters · doi:10.3892/ol.2017.7013 · Cited by 57
“A decrease in TILs significantly shortened the 5‐year overall survival and DFS in stage III tumors, and tumors of the rectum (36).”
BackgroundAyers, M., Nebozhyn, M., Cristescu, R., McClanahan, T. K., Perini, R. F., Rubin, E. H., Cheng, J. D., Kaufman, D. R., & Loboda, A. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1316 · Cited by 43
Cavalleri, T., Bianchi, P. P., Basso, G., Celesti, G., Grizzi, F., Bossi, P., Greco, L., Pitrone, C., Valtorta, E., Mauri, G., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0661 · Cited by 43
“High intra- and peri-tumoral densities of CD3þ T cells, CD8þ cytotoxic lymphocytes, and memory CD45ROþ cells predict a better postsurgical outcome (1, 2).”
BackgroundTumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC
Brockwell, N. K., Rautela, J., Owen, K. L., Gearing, L. J., Deb, S., Harvey, K., Spurling, A., Zanker, D. J., Chan, C., Cumming, H. E., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0093-2 · Cited by 44
“Further characterization of immune cells has revealed the unique role that different immune subsets play in patient prognosis with CD8 T cells remaining at the forefront of interest, where their enhanced infiltration has been associated with a good outcome in many types of cancer.(12,15,18,39,40) In TNBC, efforts to p…”
BackgroundCarlisle, J. W., Jansen, C. S., Cardenas, M. A., Sobierajska, E., Reyes, A. M., Greenwald, R., del Balzo, L., Prokhnevska, N., Küçük, Ö., Carthon, B. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004803 · Cited by 46
Advancements in Cancer Immunotherapies
Roy, R., Singh, S. K., & Misra, S. (2022) · Vaccines · doi:10.3390/vaccines11010059 · Cited by 49
Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy
Li, B., VanRoey, M. J., & Jooss, K. U. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.01.002 · Cited by 41
Garcia, S., Dalès, J.-P., Jacquemier, J. D., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603569 · Cited by 41
“…and may be a source of non-reproducible interpretation using arbitrary methods for scoring of immunostaining and lack of quality control, limited data are available in the literature concerning the automated quantification of immunoprecipitates on TMA (Camp et al, 2002; Pages et al, 2006).”
BackgroundGao, Q., Zhou, J., Wang, X., Qiu, S., Song, K., Huang, X., Sun, J., Shi, Y., Li, B., Xiao, Y., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1864-3 · Cited by 44
Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy
Liberto, D. D., Buccheri, S., Caccamo, N., et al. (2007) · Tuberculosis · doi:10.1016/j.tube.2007.01.003 · Cited by 41
Immune cell interplay in colorectal cancer prognosis
Norton, S. E., Ward-Hartstonge, K. A., Taylor, E. S., & Kemp, R. A. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i10.221 · Cited by 40
Autoantibodies in cancer: prognostic biomarkers and immune activation
Järås, K., & Anderson, K. S. (2011) · Expert Review of Proteomics · doi:10.1586/epr.11.48 · Cited by 44
LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases
Qiao, G., Qin, J., Kunda, N. M., Calata, J. F., Mahmud, D. L., Gann, P. H., Fu, Y., Rosenberg, S. A., Prabhakar, B. S., & Maker, A. V. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1655 · Cited by 43
“Cancer Immunology, Immunotherapy 2003;52(7):423-28.”
BackgroundChimeric antigen receptor T-cell therapy for glioblastoma
Rodriguez, A., Brown, C. E., & Badie, B. (2017) · Translational research · doi:10.1016/j.trsl.2017.07.003 · Cited by 48
Grizzi, F., Basso, G., Borroni, E. M., Cavalleri, T., Bianchi, P. P., Štifter, S., Chiriva‐Internati, M., Malesci, A., & Laghi, L. (2018) · Inflammation Research · doi:10.1007/s00011-017-1128-1 · Cited by 45
Yang, Y., Nam, G., Kim, G. B., Kim, Y. K., & Kim, I. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.007 · Cited by 40
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
Mylvaganam, G., Yanez, A. G., Maus, M. V., & Walker, B. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02109 · Cited by 38
“CD8 T cells (TILs) has been shown to negatively correlate with progression of colorectal metastasis (37) and oligoclonal expansions of tumor-infiltrating T cells have been associated with tumor regression (38).”
BackgroundGonzález, I., Bauer, P. S., Liu, J., & Chatterjee, D. (2020) · Histopathology · doi:10.1111/his.14211 · Cited by 44
The tumour immune landscape and its implications in cutaneous melanoma
Attrill, G. H., Ferguson, P. M., Palendira, U., Long, G. V., Wilmott, J. S., & Scolyer, R. A. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12926 · Cited by 46
“…(Her2-positive and triple-negative subtypes), liver, colorectum, ovary, endometrium and bladder (Azimi et al., 2012; Flecken et al., 2014; Galon et al., 2006; de Jong et al., 2009; Liakou et al., 2007; Pagès et al., 2005; Reynders & Ruysscher, 2016; Stanton & Disis, 2016; Zhang et al., 2003).”
BackgroundChan, M. S. M., Wang, L. Q., Felizola, S. J. A., Ueno, T., Toi, M., Loo, W. T. Y., Chow, L. W., Suzuki, T., & Sasano, H. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.10439 · Cited by 43
“High T cell infiltration with the CD8+ subset in the primary tumor tissue has been associated with better clinical outcome of patients with ovarian cancer and other malignancies (25-27).”
BackgroundSignatures Associated with Rejection or Recurrence in HER-2/ neu –Positive Mammary Tumors
Worschech, A., Kmieciak, M., Knutson, K. L., Bear, H. D., Szalay, A. A., Wang, E., Marincola, F. M., & Manjili, M. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6822 · Cited by 42
Zhang, R., Liu, H., Li, F., Li, H., Yu, J., & Ren, X. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2837-0 · Cited by 43
“In colorectal cancer, a high density of Tm within the tumor was associated with decreased invasiveness, earlier clinical stage, and prolonged survival [21–23].”
BackgroundDeficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer
Quiroga, D. M., Lyerly, H. K., & Morse, M. A. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0414-4 · Cited by 46
Zhao, J., Zhang, P., Wang, J., Xi, Q., Zhao, X., Ji, M., & Hu, G. (2017) · Medicine · doi:10.1097/md.0000000000006102 · Cited by 43
“There is evidence that tumor cells can express PD-L1 on the cell membrane by activated T-cells.([8,9]) This has been investigated in metastatic renal cell carcinoma (RCC), suggesting that primary RCC tumors with PD-L1 positivity—either on tumor cell membranes or inflammatory cells—will have a better response to PD-1/P…”
BackgroundMirjolet, C., Charon‐Barra, C., Ladoire, S., Arbez‐Gindre, F., Bertaut, A., Ghiringhelli, F., Leroux, A., Peiffert, D., Borg, C., Bosset, J. F., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1396402 · Cited by 41
Najima, Y., Yoshida, C., Iriyama, N., Fujisawa, S., Wakita, H., Chiba, S., Okamoto, S., Kawakami, K., Takezako, N., Kumagai, T., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.010 · Cited by 44
Toh, J. W. T., Phan, K. H., Reza, F., Chapuis, P. H., & Spring, K. J. (2021) · International Journal of Colorectal Disease · doi:10.1007/s00384-021-03874-1 · Cited by 48
The Invisible Arm of Immunity in Common Cancer Chemoprevention Agents
Marzbani, E., Inatsuka, C., Lu, H., & Disis, M. L. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0036 · Cited by 41
“emboli, lymphatic invasion, and perineural invasion (23).”
Abolhassani, M., Aloulou, N., Chaumette, M. T., Aparicio, T., Martin‐Garcia, N., Mansour, H., Gouvello, S. L., Delchier, J. C., & Sobhani, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1017 · Cited by 44
Xu, N., Zhu, Y., Han, Y., Liu, Q., Tong, L., Li, Y., Chen, Z., Shao, S., He, W., Li, M., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01347-1 · Cited by 50
slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells
Vermi, W., Micheletti, A., Lonardi, S., Costantini, C., Calzetti, F., Nascimbeni, R., Bugatti, M., Codazzi, M., Pinter, P., Schäkel, K., et al. (2014) · Nature Communications · doi:10.1038/ncomms4029 · Cited by 43
Maletzki, C., Jahnke, A., Ostwald, C., Klar, E., Prall, F., & Linnebacher, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032639 · Cited by 42
Girardin, A., McCall, J. L., Black, M. A., Edwards, F. J., Phillips, V., Taylor, E. S., Reeve, A. E., & Kemp, R. A. (2012) · International Journal of Cancer · doi:10.1002/ijc.27855 · Cited by 41
“, who showed a high correlation between metastatic invasion and the expression of CD8 mRNA in tumor tissue.(33) The experimental design of this study took advantage of flow cytometry to study freshly acquired patient tissue over the course of 2 years and so currently we do not have clinical outcome data available.”
BackgroundSchirrmacher, V., Fournier, P., & Schlag, P. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.854169 · Cited by 39
Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab
Goèré, D., Flament, C., Rusakiewicz, S., Poirier-Colame, V., Kepp, O., Martins, I., Pesquet, J., Eggermont, A. M. M., Elias, D. M., Chaput, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4460 · Cited by 41
Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism
Rosa, V. D., Rella, F. D., Giacomo, A. D., & Matarese, G. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.001 · Cited by 39
Hodgins, N. O., Wang, J. T.-W., & Al‐Jamal, K. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.003 · Cited by 41
on behalf of the Dutch T1 CRC Working Group, Backes, Y., Elias, S. G., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0892-7 · Cited by 38
“The tumor microenvironment and the host’s immune response have been shown to be of major importance in tumor progression [42].”
Sun, R., Champiat, S., Dercle, L., Aspeslagh, S., Álvarez, E. C., Limkin, E. J., Baldini, C., Postel-Vinay, S. C., Hollebecque, A., Massard, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.033 · Cited by 42
Theodoraki, M., Yerneni, S. S., Sarkar, S. N., Orr, B. C., Muthuswamy, R., Voyten, J., Modugno, F., Jiang, W., Grimm, M. J., Basse, P. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3985 · Cited by 42
Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer
Wy, C., Wu, C., Wang, C., et al. (2018) · Radiation Oncology · doi:10.1186/s13014-018-1099-6 · Cited by 38
IRGS: an immune-related gene classifier for lung adenocarcinoma prognosis
Shi, X., Li, R., Dong, X., Chen, A. M., Liu, X., Lu, D., Feng, S., Wang, H., & Cai, K. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02233-y · Cited by 42
FcRn expression in cancer: Mechanistic basis and therapeutic opportunities
Rudnik‐Jansen, I., & Howard, K. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.007 · Cited by 43
Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention
O’Shea, A. E., Valdera, F. A., Ensley, D. C., Smolinsky, T. R., Cindass, J. L., Bohan, P. M. K., Hickerson, A. T., Carpenter, E. L., McCarthy, P. M., Adams, A. M., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109095 · Cited by 43
The prognostic value of FOXP3+ T regulatory cells in colorectal cancer.
Vlad, C. I., Kubelac, P. M., Fetică, B., Vlad, D., Irimie, A., & Achimaș-Cădariu, P. (2015) · PubMed · Cited by 38
Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines
Sasada, T., Komatsu, N., Suekane, S., Yamada, A., Noguchi, M., & Itoh, K. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.013 · Cited by 40
Recent approaches to identifying biomarkers for high-risk stage II colon cancer
Akiyoshi, T., Kobunai, T., & Watanabe, T. (2012) · Surgery Today · doi:10.1007/s00595-012-0324-4 · Cited by 36
Hu, J., Zhu, S., Xia, X., Zhang, L., Kleinerman, E. S., & Li, S. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-34 · Cited by 38
“Infiltration of immune effector cells, such as T cells, natural killer (NK) cells, and macrophages, into tumors is known to suppress tumor cell growth [1-3].”
BackgroundShimizu, K., Yamasaki, S., Shinga, J., Sato, Y., Watanabe, T., Ohara, O., Kuzushima, K., Yagita∥, H., Komuro, Y., Asakura, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3219 · Cited by 38
“In some types of human cancer, including melanoma (33), colorectal cancer (34), breast cancer (35) and lung cancer (36), a correlation between a low density of CD8þ T cells in the tumor and poor prognosis has been reported.”
BackgroundBrody, J., Goldstein, M. J., Czerwinski, D. K., & Levy, R. (2008) · Blood · doi:10.1182/blood-2008-05-155457 · Cited by 37
Touitou, V., Daussy, C., Bodaghi, B., Camelo, S., de Kozak, Y., LeHoang, P., Naud, M., Varin, A., Thillaye-Goldenberg, B., Merle‐Béral, H., et al. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0008 · Cited by 37
“Increasing evidence suggests that the immune system regulates cancer development by several mechanisms.(3,4) This regulation can be either beneficial through immunosurveillance(5,6) or detrimental by facilitating tumor progression in many ways, such as shaping the immunophenotype of tumors, creating an immunosuppressi…”
BackgroundSelf-citationAbajo, A., Boni, V., López, I., González-Huarriz, M., Bitarte, N., Rodríguez, J., Zárate, R., Bandrés, E., & García‐Foncillas, J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.242 · Cited by 38
“However, an opposite effect has been observed in colorectal cancer, with intratumour regulatory T cells being associated with improved prognosis (Pages et al, 2005; Wagsater et al, 2008).”
BackgroundYuan, H., Hsiao, Y.-H., Zhang, Y., Wang, J., Yin, C., Shen, R., & Su, Y. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-258 · Cited by 38
“A large number of publications have reported that the direct physical contact between infiltrated immune cells and tumor cells is associated with the physical destruction of associated tumor cells, reduction of the tumor size, and significantly improved clinical prognoses [1-6].”
BackgroundBerencsi, K., Rani, P., Zhang, T., Gross, L. A., Mastrangelo, M. J., Meropol, N. J., Herlyn, D., & Somasundaram, R. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-33 · Cited by 46
“and [15-19]).”
Colorectal cancer and therapy response: a focus on the main mechanisms involved
Tirendi, S., Marengo, B., Domenicotti, C., Bassi, A. M., Almonti, V., & Vernazza, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1208140 · Cited by 42
Allard, M., Bachet, J., Beauchet, A., Julié, C., Malafosse, R., Penna, C., Nordlinger, B., & Emile, J. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-156 · Cited by 40
“This approach has been adopted by several authors, mostly using TMA [5,12].”
BackgroundMethodInfluentialWang, X., Hassan, W., Jabeen, Q., Khan, G. J., & Iqbal, F. M. (2017) · Cytokine · doi:10.1016/j.cyto.2017.09.026 · Cited by 37
Miller, T. J., McCoy, M. J., Hemmings, C., Bulsara, M. K., Iacopetta, B. M., & Platell, C. F. E. (2017) · Pathology · doi:10.1016/j.pathol.2017.08.007 · Cited by 38
Regulation of CTL Infiltration Within the Tumor Microenvironment
Church, S., & Galon, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_3 · Cited by 37
Self-citationTumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score
Dawson, H., Christe, L., Eichmann, M. D., Reinhard, S., Zlobec, I., Blank, A., & Lugli, A. (2020) · Histopathology · doi:10.1111/his.14006 · Cited by 40
Kroemer, M., Turco, C., Spehner, L., Viot, J., Idirène, I., Bouard, A., Renaude, E., Deschamps, M., Godet, Y., Adotévi, O., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001478 · Cited by 40
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang, C., & Fakih, M. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1933940 · Cited by 41
“Early studies by Galon and colleagues showed that levels of immune infiltration in primary tumors have prognostic significance in colorectal cancer [3].”
BackgroundAporta, A., Catalán, E., Galán‐Malo, P., Ramírez-Labrada, A., Pérez-Hernández, M., Azaceta, G., Palomera, L., Naval, J., Marzo, I., Pardo, J., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.004 · Cited by 43
“Furthermore, clinical studies have shown that the prognosis of cancer patients is better in those expressing greater amounts of granulysin in their NK cells or memory CTL [4–7].”
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer
Aka, A. A., Rappaport, J. A., Pattison, A. M., Sato, T., Snook, A. E., & Waldman, S. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1292124 · Cited by 39
“For example, the presence of lymphocytes in CRC tumors is associated with delayed metastasis and prolonged survival [59].”
Shaping of an effective immune microenvironment to and by cancer cells
Becht, É., Goc, J., Germain, C., Giraldo, N. A., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1590-3 · Cited by 37
“Nevertheless, since the composition of the immune microenvironment of primary tumors in patients with lymph node metastases remains a prognostic factor [25], it strongly suggests that there are extranodal sites for generating the tumor-targeted adaptive immune response.”
BackgroundSelf-citationKim, Y.-H., Bae, J. M., Li, G., Cho, N., & Kang, G. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122183 · Cited by 39
“6 mm to 1 mm diameter) used in previous studies [11,19,21,26] to exclude the possible effects of tumor heterogeneity.”
BackgroundMethodModulation of tumor immunity by therapeutic monoclonal antibodies
Abès, R., & Teillaud, J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9282-3 · Cited by 37
“The study reported by Galon and his colleagues [ 3 , 4] with tumors derived from hundreds of patients has shown that the development of colon carcinoma in humans results from a complex process where tumors cells and immune cells are engaged in a mortal combat, demonstrating that immunosurveillance is a critical mechan…”
ResultRelationship between Colonic Polyp Type and the Neutrophil/Lymphocyte Ratio as a Biomarker
Karaman, H., Karaman, A., Erden, A., et al. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.5.3159 · Cited by 35
“Many cancer survival studies have suggested that NLR is a significant predictor of overall and disease specific survival of patients (Mc Millan et al., 2003; Al et al., 2004; Pages et al., 2005; Walsh et al., 2005; Cho et al., 2008; Halazun et al., 2008; An et al., 2010; Saito et al., 2010; Ubukata et al., 2010; Chua…”
BackgroundMicroRNA MIR21 and T Cells in Colorectal Cancer
Mima, K., Nishihara, R., Nowak, J. A., Kim, S. A., Song, M., Inamura, K., Sukawa, Y., Masuda, A., Yang, J., Dou, R., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0084 · Cited by 37
“The favorable prognostic associations of the densities of these T-cell populations in our cohort studies were consistent with the results of previous studies in other populations (6, 8), suggesting that the density of T cells, as assessed by immunohistochemistry, might be considered a reliable measure of the adaptive…”
ResultThe influence of physical activity in the anti-tumor immune response in experimental breast tumor
Bianco, T. M., Abdalla, D. R., Desidério, C. S., Thys, S., Simoens, C., Bogers, J., Murta, E. F. C., & Michelin, M. A. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.007 · Cited by 39
“, melanoma, colorectal, and ovarian cancer) [53-58].”
Fujimoto, H., Saito, Y., Ohuchida, K., Kawakami, E., Fujiki, S., Watanabe, T., Ono, R., Kaneko, A., Takagi, S., Najima, Y., et al. (2018) · Journal of Immunology · doi:10.4049/jimmunol.1701222 · Cited by 32
“Our findings correlating impaired function with the maturation status of EM CTLs in colorectal adenocarcinoma is consistent with a previous study showing the association between the development of memory CD8 T cells and the prognosis for colorectal cancer patients (41).”
ResultAhmadvand, S., Faghih, Z. S., Montazer, M., Safaei, A., Mokhtari, M., Jafari, P., Talei, A., Tahmasebi, S., & Ghaderi, A. A. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00430-6 · Cited by 43
Trabelsi, M., Farah, F., Zouari, B., Jaafoura, M. H., & Kharrat, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s211048 · Cited by 43
“Galon and Pagès showed that tumor-infiltrating lymphocytes, especially with CD3, are directly correlated with micro-invasive status and the presence of CD8 T-cells in the center of the tumor suggests their essential role in the immune response and disease outcome.(2,30) However, the anti-tumoral immunity promotes the…”
BackgroundHassan, G., & Seno, M. (2020) · Cells · doi:10.3390/cells9051293 · Cited by 43
“In normal tissue, immune cells provide defense responses, whereas in the TME, the functions of these cells principally depend on cancer stage, interaction with other cells, and their subtypes [2,4,8,42].”
BackgroundSumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 38
Integrin β7 Inhibits Colorectal Cancer Pathogenesis via Maintaining Antitumor Immunity
Zhang, Y., Xie, R., Zhang, H., Zheng, Y., Lin, C., Yang, L., Huang, M., Li, M., Song, F., Lu, L., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0879 · Cited by 40
Martini, M., Ferrara, A. M., Giachelia, M., Panieri, E., Siminovitch, K., Galeotti, T., Larocca, L. M., & Pani, G. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21814 · Cited by 37
Regulation of tumor immunity: the role of NKT cells
Ambrosino, E., Berzofsky, J. A., & Terabe, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.725 · Cited by 39
“Furthermore, in case of ovarian carcinomas, the presence of intratumoral T cells correlated with delayed recurrence or delayed death [18] , and in colorectal cancer patients, the presence of high levels of infiltrating memory T cells correlated with absence of signs of early metastatic invasion and with increased surv…”
BackgroundOrganotypic three-dimensional assays based on human leiomyoma–derived matrices
Salo, T. A., Dourado, M. R., Sundquist, E., Apu, E. H., Alahuhta, I., Tuomainen, K., Vasara, J., & Al‐Samadi, A. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0482 · Cited by 38
Kanno, H., Miyoshi, H., Yoshida, N., Sudo, T., Nakashima, K., Takeuchi, M., Nomura, Y., Seto, M., Hisaka, T., Tanaka, H., et al. (2020) · Cancer Science · doi:10.1111/cas.14495 · Cited by 33
The clinical significance of memory T cells and its subsets in gastric cancer
Zhang, R., Li, F., Li, H., Yu, J., & Ren, X. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1066-5 · Cited by 37
Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy
Roliński, J., & Hus, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.865094 · Cited by 36
“It has also been shown that a presence of immune cell infiltrates in cancer tissues correlate with a better prognosis (Movassagh et al., 2004; Pagès et al., 2005; Wansom et al., 2012).”
BackgroundMadhavan, S., Gusev, Y., Natarajan, T. G., Song, L., Bhuvaneshwar, K., Gauba, R., Pandey, A., Haddad, B. R., Goerlitz, D. S., Cheema, A. K., et al. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00236 · Cited by 37
de Boniface, J., Poschke, I. C., Mao, Y., & Kiessling, R. W. (2011) · International Journal of Cancer · doi:10.1002/ijc.26355 · Cited by 34
Shigematsu, Y., Hanagiri, T., Shiota, H., Kuroda, K., Baba, T., Ichiki, Y., Yasuda, M., Uramoto, H., Takenoyama, M., Yasumoto, K., et al. (2012) · Oncology Letters · doi:10.3892/ol.2012.815 · Cited by 35
“A high level of CD8 T cell infiltration into tumor tissues has been reported to be associated with a better prognosis in colon carcinoma and in ovarian cancer, suggesting that antitumor immunity can be provoked in cancer patients (7,8).”
Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases
Grimm, M. R., Gasser, M., Bueter, M., Strehl, J. D., Wang, J., Nichiporuk, E., Meyer, D., Germer, C. T., Waaga-Gasser, A. M., & Thalheimer, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-82 · Cited by 34
“In colon cancer the expression of Th1-associated genes like IFN-g, which exerts antiproliferative, antiangiogenic, and proapoptotic effects on a variety of tumor cells [39,40], was significantly associated with a more favourable clinical course of the disease [41].”
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
Junghans, R. P. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2016.82 · Cited by 37
Hope, J. L., Stairiker, C. J., Bae, E., Otero, D. C., & Bradley, L. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01595 · Cited by 45
“resections and were associated with increased survival in patients and noted a positive correlation between the infiltration of “memory-like” CD8 T cells and patient survival (168).”
BackgroundIntegration of Salmonella into Combination Cancer Therapy
Al-Saafeen, B. H., Fernández-Cabezudo, M. J., & al-Ramadi, B. K. (2021) · Cancers · doi:10.3390/cancers13133228 · Cited by 40
Lucarini, V., Melaiu, O., D’Amico, S., Pastorino, F., Tempora, P., Scarsella, M., Pezzullo, M., Ninno, A. D., Doria, V., Cilli, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02525-9 · Cited by 38
Well-established immunotherapy with R837-loaded boron neutron capture-shocked tumor cells
Chen, K., Liu, S., Lv, L., Tong, J., Chen, J., Liang, H., Wang, Y., Hu, F., Liu, Q., Li, H., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101995 · Cited by 35
Angell, H. K., Gray, N. M., Womack, C., Pritchard, D. I., Wilkinson, R. W., & Cumberbatch, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.487 · Cited by 39
“…cell infiltration in the tumour microenvironment is a strong parameter influencing clinical outcome, regardless of tumour burden (Naito et al, 1998; Pages et al, 2005, 2008; Galon et al, 2006; Camus et al, 2009; Halama et al, 2009; Salama et al, 2009; Mlecnik et al, 2011; Tosolini et al, 2011).”
BackgroundTumor-Infiltrating Mast Cells in Colorectal Cancer as a Poor Prognostic Factor
Wu, X., Zou, Y., He, X., Yuan, R., Chen, Y., Lan, N., Lian, L., Wang, F., Fan, X., Zeng, Y., et al. (2012) · International Journal of Surgical Pathology · doi:10.1177/1066896912448836 · Cited by 34
Halama, N., Zoernig, I., Spille, A., Westphal, K., Schirmacher, P., Jaeger, D., & Grabe, N. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007847 · Cited by 35
“It is important to note that the observed immune cell densities were better predictors of prognosis than the classical TNM classification [4–6], initiating a debate on the feasibility of individualized prognosis prediction based on immune cell densities.”
BackgroundWu, S., Wang, Y., Zhou, J., et al. (2015) · PubMed · Cited by 34
Märkl, B., Wieberneit, J., Kretsinger, H., Mayr, P., Anthuber, M., Arnholdt, H., & Schenkirsch, G. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw074 · Cited by 33
“102 Lymphatic invasion 5 (3) 1 (2) 2 (3) 0 NC 3 (4) 0 0 NC Venous invasion 5 (3) 2 (4) 1 (2) 1 (3) NC 3 (4) 0 1 (4) NC Distant metastases 13 (8) 6 (11) 6 (10) 0 .”
Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score
Khan, A. M., & Yuan, Y. (2016) · Scientific Reports · doi:10.1038/srep36231 · Cited by 34
Xue, K., Liu, L., Liu, Y., Guo, Y., Zhu, Y., & Zhang, M. (2022) · La radiologia medica · doi:10.1007/s11547-022-01507-3 · Cited by 38
Metadata
- Authors
- Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., Meatchi, T., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Galon, J.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Graz University of Technology (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-22
- Volume
- 353
- Issue
- 25
- Pages
- 2654-2666
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096151993
- Semantic Scholar
- 608c79dfb95b1632f3cda7f427350880ee435e8a
- Cited by
- 2,135
- References
- 32
- Citations by year
- 2026: 27 · 2025: 57 · 2024: 66 · 2023: 118 · 2022: 117 · 2021: 141 · 2020: 130 · 2019: 123 · 2018: 123 · 2017: 136 · 2016: 135 · 2015: 145 · 2014: 115 · 2013: 135 · 2012: 108
- FWCI
- 27.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- colorectal cancer, effector memory T cells, tumor-infiltrating lymphocytes, CD8+ T cells, CD45RO+ memory T cells, T-cell markers, lymphatic invasion, perineural invasion, interferon-gamma, granzyme B, granulysin, IRF1, disease-free survival, overall survival, antitumor immunity
- MeSH terms
- Analysis of Variance, Embolism, Flow Cytometry, Humans, Lymphatic Metastasis, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, RNA, Messenger, T-Lymphocytes, Colorectal Neoplasms, Gene Expression, Proportional Hazards Models, Survival Analysis, Polymerase Chain Reaction, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Microarray Analysis, Protein Tyrosine Phosphatase, Non-Receptor Type 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.